To date, we’ve published a dozen posts either detailing, or mentioning-in-passing, the clinical and financial benefits a well-run Meds To Beds program offers hospitals and the patients they serve. Which is why we thought it was time to report some of the personal benefits our program delivers — with a handful of stories we’ve heard … Read More
Why a Specialty Pharmacy? (Overview) As chronic illnesses become increasingly common in the United States, the number of specialty medications for managing these conditions has skyrocketed. According to a report by The American Hospital Association, the number of Americans with chronic medical conditions will grow by a projected 9% between 2020 and 2030, an increase … Read More
In the past week, no less than three articles have called attention to the restrictions drug manufacturers have imposed to evade their legal responsibility to honor 340B program prescription discounts — as well as the impact those restrictions have had on 340B-eligible nonprofit entities’ ability to serve their patients and communities. “Don’t believe drug companies: … Read More
(Photo above: ProxsysRx’s pharmacy at Terrebonne General Health System, in Houma, LA) The Retail Component “Dawn Dobersztyn does not get enough credit,” says ProxsysRx COO Billy Calhoun. “When you think about it, retail is the face of our pharmacies. It’s the first thing people see when they walk in the door. And here’s the thing: … Read More
On June 12, ProxsysRx opened its pharmacy in Holyoke Medical Center — a 198-bed independent community hospital in Holyoke, Massachusetts. The pharmacy is currently offering full retail service, and some patient-discharge prescription support (Meds To Beds), but the Employee Prescription plan still has a few hurdles to overcome. It’s a still-unfinished process that began when … Read More
In late 2022, ProxsysRx’s team initiated 340B Program-Management support for a 198-bed, full-service, community and regional non-profit medical center located in the Northeast. After weeks of laying all the necessary groundwork to manage its 340B program, we began actively submitting eligible prescriptions this past January. By the end of Q1, the hospital’s 2023 340B savings … Read More
The 340B-program landscape has changed dramatically. For the 340B program’s first 28 years after its 1992 inception, the basic list of Best Practices for eligible entities remained largely unchanged — aside from the dramatically-increased importance of using specialized software. But since the June, 2020 introduction of 340B ESP — which has led to an avalanche … Read More
MedServRx: No prescription card saves more. Or delivers more. Not only does MedServRx offer savings of up to 80% (sometimes even more), it gives participating self-insured companies access to prescription-fulfillment data that’s commonly lost when patients use other prescription-discount cards. The MedServRx card, and all of the prescription-data reporting it delivers, are available at no … Read More
340B ESP and drug manufacturer restrictions are only part of the reason As we noted in a previous post, for 340B-eligible hospitals dealing with increasingly squeezed bottom lines, an in-house specialty pharmacy offers enormous savings and revenue potential. Some covered entities generate as much as 600% in specialty pharmacy revenue from 340B drugs as they … Read More
There’s an old saying that it’s better to be rich and guilty than poor and innocent. It’s a sad truth that accurately reflects the current state of 340B manufacturer restrictions, particularly in the wake of the January 30, 2023 decision by the U.S. Court of Appeals for the Third Circuit — which was largely in … Read More
